Xanthine oxidase-IN-23
Xanthine oxidase-IN-23 (Compound BPF) is an orally active, reversible, mixed-type Xanthine oxidase inhibitor with an IC50 of 3.33 μM. Xanthine oxidase-IN-23 directly binds to XOD in a reversible mixed-type manner to inhibit its catalytic activity. Xanthine oxidase-IN-23 upregulates ABCG2 and downregulates GLUT9 to promote renal urate excretion. Xanthine oxidase-IN-23 reduces serum urate levels and improves renal function in hyperuricemic mice. Xanthine oxidase-IN-23 can be used in the research of hyperuricemia.
For research use only. We do not sell to patients.
- CAS No.: 3055112-52-9
- Formula: C17H12Br2O5
- Molecular Weight:456.08
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
GLUT9 |
Xanthine oxidase-IN-23 (15 min) potently inhibits purified xanthine oxidase via a reversible mixed-type inhibition mode, with an IC50 of 3.33 μM[1].
Xanthine oxidase-IN-23 (0.5-8 μM) exhibits potent DPPH free radical scavenging activity, with a scavenging rate of over 50% at 2 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Kunming mice (male, 5 weeks old, 39.4 g)[1]
-
Dosage:100 mg/kg; 200 mg/kg
-
Administration:p.o.; single dose
-
Result:Significantly reduced serum uric acid (SUA) levels compared to the hyperuricemia model group.
Significantly reduced hepatic uric acid levels and hepatic xanthine oxidase (XOD) activity compared to the model group (200 mg/kg dose).
Completely reversed the downregulation of renal uric acid secretion transporter ABCG2 while significantly downregulating renal uric acid reabsorption transporter GLUT9 (200 mg/kg dose).
Significantly restored elevated serum creatinine (CRE) levels to near normal and mitigated hyperuricemia-induced mild renal tubular dilation and eosinophilic material accumulation.
Increased urinary uric acid levels at early time points after modeling compared to the model group (200 mg/kg dose).
Caused no significant changes in hepatic index, serum alanine aminotransferase (ALT), or aspartate aminotransferase (AST) levels, indicating no liver injury.
Chemical Information
-
CAS No. 3055112-52-9
-
Molecular Weight 456.08
-
Formula C17H12Br2O5
-
SMILES
O=C(/C=C/C1=CC(O)=C(O)C=C1Br)/C=C/C2=CC(O)=C(O)C=C2Br
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Xanthine oxidase-IN-23 Related Classifications
HY-182000 Related Classifications
Powered by Bioz